Healthcare / Pharmaceutical RetailersMilan
$6.20
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 62.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$39M
P/E
31.0x
↑EV/EBITDA
15.3x
↑ROE
5.5%
↑Gross Margin
36.5%
↓Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2024 · 1 años de histórico normalizado
Revenue CAGR
+3.9%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $26.1M · net income $1.3M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $26.1M | $26.1M | $25.1M |
| Net Income | $1.3M | $1.3M | $1.5M |
| EBITDA | $3.2M | $3.2M | $3.5M |
| EPS | — | — | 0.23 |
| Gross Margin | 36.5% | 36.5% | 35.1% |
| Operating Margin | 9.7% | 9.7% | 11.1% |
| Net Margin | 4.8% | 4.8% | 5.9% |
| Balance Sheet | |||
| Debt/Equity | 0.42 | 0.42 | 0.49 |
| Current Ratio | 0.35 | 0.35 | — |
| Returns | |||
| ROE | 5.5% | 5.5% | 6.8% |
| Valuation | |||
| P/E | 31.00 | 31.00 | — |
| EV/EBITDA | 15.26 | 15.26 | — |
| P/B | 1.74 | 1.74 | — |
| Growth & Yield | |||
| Revenue Growth | 3.9% | 3.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.23 → n/d
Residual
+6.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.